Immix Biopharma (IMMX) Income from Non-Controlling Interests (2023 - 2024)

Immix Biopharma has reported Income from Non-Controlling Interests for 3 years, with the latest figure at $69141.0 in Q1 2026.

• Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $69141.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56227.0 (changed N/A YoY) and the FY2024 annual result came in at -$84987.0, up 49.85% from the prior year.
• Income from Non-Controlling Interests grew to $69141.0 in Q1 2026 per IMMX's latest filing, from -$12914.0 in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $69141.0 in Q1 2026 and troughed at -$72073.0 in Q1 2024.
• A 3-year average of -$26474.3 and a median of -$21996.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 41.29% in 2024, down 292.38% in 2024.
• Over 3 years, Income from Non-Controlling Interests stood at -$65862.0 in 2023, then jumped by 80.39% to -$12914.0 in 2024, then jumped by 635.4% to $69141.0 in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $69141.0, -$12914.0, and -$72073.0 for Q1 2026, Q2 2024, and Q1 2024 respectively.